On March 7, 2022, Liam Ratcliffe, MD, Ph.D., notified Passage Bio, Inc. of his decision to resign from the company's Board of Directors, including from the Nominating and Governance Committee of the Board, effective immediately. Dr. Ratcliffe's decision to resign was due to a disagreement with the Company regarding its business plans and operations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.31 USD | -0.76% | -11.49% | +29.70% |
May. 15 | Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating | MT |
Mar. 04 | Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.70% | 81.33M | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- PASG Stock
- News Passage Bio, Inc.
- Passage Bio, Inc. Announces Resignation of Liam Ratcliffe from the Board of Directors and Member of Nominating and Governance Committee